Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367794 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,021
- Enrollment target
NCT02367794: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT02367794 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,021 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367794, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,021 participants
- Enrollment target
Study Summary
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Primary Outcome
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Nab-Paclitaxel
- DRUG Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,021 participants |
| Start Date | 2015-06-11 |
| Est. Completion | 2021-02-17 |
| Phase | Phase 3 |
What the finished NCT02367794 record still lists
NCT02367794 is an interventional study that assigns participants to a tested intervention. Its 1,021 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02367794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02367794 about?
NCT02367794 is a clinical study titled "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]". This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
What is the current status of trial NCT02367794?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,021 participants. The study started on 2015-06-11. Estimated completion is 2021-02-17.
What interventions are being tested in trial NCT02367794?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Nab-Paclitaxel (DRUG), Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody (DRUG).
Who is sponsoring clinical trial NCT02367794?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02367794's enrollment target sits among peer trials
1,021 290th of 2000 higher than 1,710 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI